Clinical Significance of Serum Hemeoxygenase-1 as a New Biomarker for the Patients with Interstitial Pneumonia
Kota Murohashi
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan yokohama-cu.ac.jp
Search for more papers by this authorCorresponding Author
Yu Hara
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan yokohama-cu.ac.jp
Search for more papers by this authorKanako Shinada
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan yokohama-cu.ac.jp
Search for more papers by this authorKenjiro Nagai
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan yokohama-cu.ac.jp
Search for more papers by this authorMasaharu Shinkai
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan yokohama-cu.ac.jp
Department of Pulmonology, Tokyo-Shinagawa Hospital, Shinagawa, Japan
Search for more papers by this authorAkihiko Kawana
Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan ndmc.ac.jp
Search for more papers by this authorTakeshi Kaneko
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan yokohama-cu.ac.jp
Search for more papers by this authorKota Murohashi
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan yokohama-cu.ac.jp
Search for more papers by this authorCorresponding Author
Yu Hara
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan yokohama-cu.ac.jp
Search for more papers by this authorKanako Shinada
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan yokohama-cu.ac.jp
Search for more papers by this authorKenjiro Nagai
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan yokohama-cu.ac.jp
Search for more papers by this authorMasaharu Shinkai
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan yokohama-cu.ac.jp
Department of Pulmonology, Tokyo-Shinagawa Hospital, Shinagawa, Japan
Search for more papers by this authorAkihiko Kawana
Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan ndmc.ac.jp
Search for more papers by this authorTakeshi Kaneko
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan yokohama-cu.ac.jp
Search for more papers by this authorAbstract
Background. Serum hemeoxygenase-1 (HO-1) has been proposed to be a biomarker of lung disease activity and prognosis. The present study aimed at evaluating whether HO-1 could be a useful marker for evaluating disease activity and predicting prognosis in patients with interstitial pneumonia (IP). Materials and Methods. Serum HO-1 levels of newly diagnosed or untreated patients with IP were measured at hospitalization. We evaluated the relationships between serum HO-1 and other serum biomarkers, high resolution CT (HRCT) findings, and hospital mortality. Results. Twenty-eight patients with IP, including 14 having an acute exacerbation (AE) and 14 not having an AE, were evaluated. The patients having an AE had significantly higher HO-1 levels than those not having an AE (53.5 ng/mL vs. 24.1 ng/mL; p < 0.001), and the best cut-off level to discriminate between having an AE or not having an AE was 41.6 ng/mL. Serum HO-1 levels were positively correlated with serum levels of surfactant protein-D (r = 0.66, p < 0.001) and the ground glass opacity score (calculated from HRCT; r = 0.40, p = 0.036). Patients who subsequently died in hospital had presented with significantly higher HO-1 levels than those who did not die in hospital (64.8 ng/mL vs. 32.0 ng/mL; p = 0.009). Conclusion. Serum HO-1 may serve as a useful biomarker for detecting AE or predicting hospital mortality in patients with IP.
Open Research
Data Availability
The table and figure data used to support the findings of this study are included within the article.
Supporting Information
| Filename | Description |
|---|---|
| carj7260178-sup-0001-f1.pptxPowerPoint 2007 presentation , 2.5 MB | Supplementary Materials Immunohistochemical staining for hemeoxygenase-1 (HO-1) expression in lung specimens (A). Bacterial pneumonia (B). Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) (C). Stable IPF in an AE-IPF patient (autopsy case); high expression of HO-1 was observed mainly in alveolar macrophages, while expression of HO-1 in fibrotic lesions/alveolar macrophages was not conspicuous in stable IPF (the specimen of surgical lung biopsy) (original magnification × 200). |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Choi A. M. and Alam J., Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury, American Journal of Respiratory Cell and Molecular Biology. (1996) 15, no. 1, 9–19, https://doi.org/10.1165/ajrcmb.15.1.8679227, 2-s2.0-0030188587.
- 2 Ryter S. W., Kim H. P., Nakahira K., Zuckerbraun B. S., Morse D., and Choi A. M., Protective functions of heme oxygenase-1 and carbon monoxide in the respiratory system, Antioxidants and Redox Signaling. (2007) 9, no. 12, 2157–2173, https://doi.org/10.1089/ars.2007.1811, 2-s2.0-35848966362.
- 3 Li N., Venkatesan M. I., Miguel A. et al., Induction of heme oxygenase-1 expression in macrophages by diesel exhaust particle chemicals and quinones via the antioxidant-responsive element, Journal of Immunology. (2000) 165, no. 6, 3393–3401, https://doi.org/10.4049/jimmunol.165.6.3393, 2-s2.0-0034665324.
- 4 Lakari E., Pylkas P., Pietarinen-Runtti P., Paakko P., Soini Y., and Kinnula V. L., Expression and regulation of hemeoxygenase 1 in healthy human lung and interstitial lung disorders, Human Pathology. (2001) 32, no. 11, 1257–1263, https://doi.org/10.1053/hupa.2001.28937, 2-s2.0-0035179226.
- 5 Bargagli E., Olivieri C., Bennett D., Prasse A., Muller-Quernheim J., and Rottoli P., Oxidative stress in the pathogenesis of diffuse lung diseases: a review, Respiratory Medicine. (2009) 103, no. 9, 1245–1256, https://doi.org/10.1016/j.rmed.2009.04.014, 2-s2.0-68049129556.
- 6 Mumby S., Upton R. L., Chen Y. et al., Lung heme oxygenase-1 is elevated in acute respiratory distress syndrome, Critical Care Medicine. (2004) 32, no. 5, 1130–1135, https://doi.org/10.1097/01.ccm.0000124869.86399.f2, 2-s2.0-2442477550.
- 7 Sato T., Takeno M., Honma K. et al., Heme oxygenase-1, a potential biomarker of chronic silicosis, attenuates silica-induced lung injury, American Journal Respiratory and Critical Care Medicine. (2006) 174, no. 8, 906–914, https://doi.org/10.1164/rccm.200508-1237oc, 2-s2.0-33749833683.
- 8 Sato T., Saito Y., Inoue S. et al., Serum hemeoxygenase-1 as a marker of lung function decline in patients with chronic silicosis, Journal of Occupational and Environmental Medicine. (2012) 54, no. 12, 1461–1466, https://doi.org/10.1097/jom.0b013e3182636e93, 2-s2.0-84871795561.
- 9 Sheu C. C., Zhai R., Wang Z. et al., Heme oxygenase-1 microsatellite polymorphism and haplotypes are associated with the development of acute respiratory distress syndrome, Intensive Care Medicine. (2009) 35, no. 8, 1343–1351, https://doi.org/10.1007/s00134-009-1504-6, 2-s2.0-67650995464.
- 10 Hara Y., Shinkai M., Kanoh S. et al., Clinico-pathological analysis referring hemeoxygenase-1 in acute fibrinous and organizing pneumonia patients, Respiratory Medicne Case Report. (2015) 14, 53–56, https://doi.org/10.1016/j.rmcr.2015.01.003, 2-s2.0-84922638390.
- 11 Hara Y., Shinkai M., Taguri M., Nagai K., Hashimoto S., and Kaneko T., ELISA development for serum hemeoxygenase-1 and its application to patients with acute respiratory distress syndrome, Canadian Respiratory Journal. (2018) 2018, 7, 9627420, https://doi.org/10.1155/2018/9627420, 2-s2.0-85048642759.
- 12 Travis W. D., Costabel U., Hansell D. M. et al., ATS/ERS committee on idiopathic interstitial pneumonias: an official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias, American Journal of Respiratory and Critical Care Medicine. (2013) 188, no. 6, 733–748, https://doi.org/10.1164/rccm.201308-1483st, 2-s2.0-84881669432.
- 13 Travis W. D., Hunninghake G., KingT. E.Jr. et al., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project, American Journal of Respiratory and Critical Care Medicine. (2008) 177, no. 12, 1338–1347, https://doi.org/10.1164/rccm.200611-1685oc, 2-s2.0-44949225988.
- 14 Collard H. R. l, Moore B. B., Flaherty K. R. et al., Idiopathic pulmonary fibrosis clinical research network investigators acute exacerbations of idiopathic pulmonary fibrosis, American Journal of Respiratory and Critical Care Medicine. (2007) 176, no. 7, 636–643, https://doi.org/10.1164/rccm.200703-463pp, 2-s2.0-34848821215.
- 15 Hyzy R., Huang S., Myers J., Flaherty K., and Martinez F., Acute exacerbation of idiopathic pulmonary fibrosis, Chest. (2007) 132, no. 5, 1652–1658, https://doi.org/10.1378/chest.07-0299, 2-s2.0-36348946221.
- 16 Park I. N., Kim D. S., Shim T. S. et al., Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis, Chest. (2007) 132, no. 1, 214–220, https://doi.org/10.1378/chest.07-0323, 2-s2.0-34447522198.
- 17 Ooi G. C., Mok M. Y., Tsang K. W. et al., Interstitial lung disease in systemic sclerosis, Acta Radiologica. (2003) 44, no. 3, 258–264, https://doi.org/10.1034/j.1600-0455.2003.00058.x, 2-s2.0-0037630050.
- 18 Ryter S. W. and Choi A. M., Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation, Translation Research. (2016) 167, no. 1, 7–34, https://doi.org/10.1016/j.trsl.2015.06.011, 2-s2.0-84952637046.
- 19 Hara Y., Shinkai M., Kanoh S. et al., Arterial carboxyhemoglobin measurement is useful for evaluating pulmonary inflammation in subjects with interstitial lung disease, Internal Medicine. (2017) 56, no. 6, 621–626, https://doi.org/10.2169/internalmedicine.56.7418, 2-s2.0-85015662203.
- 20 Takahashi H., Shiratori M., Kanai A., Chiba H., Kuroki Y., and Abe S., Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D, Respirology. (2006) 11, S51–S54, https://doi.org/10.1111/j.1440-1843.2006.00809.x, 2-s2.0-33645104610.
- 21 Ohnishi H., Yokoyama A., Kondo K. et al., Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases, American Journal of Respiratory and Critical Care Medicine. (2002) 165, no. 3, 378–381, https://doi.org/10.1164/ajrccm.165.3.2107134, 2-s2.0-0036469096.
- 22 Takahashi H., Fujishima T., Koba H. et al., Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent, American Journal of Respiratory and Critical Care Medicine. (2000) 162, no. 3, 1109–1114, https://doi.org/10.1164/ajrccm.162.3.9910080, 2-s2.0-0033825445.
- 23 Nayak A., Dodagatta-Marri E., Tsolaki A. G., and Kishore U., An insight into the diverse roles of surfactant proteins, SP-a and SP-D in innate and adaptive immunity, Frontiers in Immunology. (2012) 3, https://doi.org/10.3389/fimmu.2012.00131, 2-s2.0-84871710260.
- 24 Gargiulo P., Banfi C., Ghilardi S. et al., Surfactant-derived proteins as markers of alveolar membrane damage in heart failure, PLoS One. (2014) 9, no. 12, e115030, https://doi.org/10.1371/journal.pone.0115030, 2-s2.0-84919360899.
- 25 Spoorenberg S. M., Vestjens S. M., Rijkers G. T. et al., YKL-40, CCL18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia, Respirology. (2017) 22, no. 3, 542–550, https://doi.org/10.1111/resp.12924, 2-s2.0-85000399540.
- 26 Kishaba T., Tamaki H., Shimaoka Y., Fukuyama H., and Yamashiro S., Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis, Lung. (2014) 192, no. 1, 141–149, https://doi.org/10.1007/s00408-013-9530-0, 2-s2.0-84894029673.
